Breaking News

RedHill Awarded $1.7M in Government Funding for Opaganib

Opaganib is being developed for multiple indications, including COVID-19, acute respiratory distress syndrome, and oncology.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, reported that opaganib has been awarded a further $1.7 million in U.S. Government funding, via a Small Business Innovation Research (SBIR) grant to the company’s development partner, Apogee Biotechnology Corp. The SBIR grant will support research to further the development of opaganib as a medical countermeasure (MCM) for gastrointestinal acute radiation syndrome (GI-ARS). This grant is in addition and complementary to the mult...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters